Filing Details

Accession Number:
0001209191-11-027255
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-05-10 17:10:15
Reporting Period:
2011-05-09
Filing Date:
2011-05-10
Accepted Time:
2011-05-10 16:10:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1349077 Lisa Kelly C/O Vertex Pharmaceuticals Incorporated
130 Waverly St
Cambridge MA 02139
Svp, Human Resources No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-05-09 1,906 $18.93 44,148 No 4 M Direct
Common Stock Disposition 2011-05-09 300 $55.72 43,848 No 4 S Direct
Common Stock Disposition 2011-05-09 530 $56.69 43,318 No 4 S Direct
Common Stock Disposition 2011-05-09 1,076 $57.53 42,242 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2011-05-09 1,906 $0.00 1,906 $18.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,719 2008-08-15 2018-05-14 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,182 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $55.72 (range $55.52 to $55.90).
  3. Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $56.69 (range $56.22 to $56.97).
  5. Open market sales reported on this line occurred at a weighted average price of $57.53 (range $57.13 to $57.90).
  6. Right to buy under 2006 Stock and Option Plan vesting in 16 quarterly installments from 02/07/2008.